Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104

Next Previous
Trial Profile

A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IRL 201104 (Primary) ; IRL 201104 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Immune Regulation; Peptinnovate; Revolo Biotherapeutics

Most Recent Events

  • 26 Nov 2018 Results presented in an Immune Regulation Media Release.
  • 22 Nov 2018 According to an Immune Regulation media release, Peptinnovate acquired Immune Regulation Ltd. earlier this year and today the company announced that that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect.
  • 23 Jan 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top